# Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

> **NCT04748042** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Prostate Cancer
- Castrate Sensitive Prostate Cancer
- Oligometastatic Disease

## Interventions

- **DRUG:** Abiraterone
- **DRUG:** Prednisone
- **RADIATION:** External Beam Radiotherapy
- **BIOLOGICAL:** Androgen Deprivation Therapy (ADT)
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT04748042
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-28
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04748042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04748042, "Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04748042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*